Matinas biopharma reports third quarter 2020 financial results and operational highlights

Enact study of mat2203 in cryptococcal meningitis received unanimous d ata and safety monitoring board (dsmb) recommendation to pro ceed into second patient cohort

MTNB Ratings Summary

MTNB Quant Ranking